Biogen Adds Two More Biosimilars in $100M Deal with Samsung Bioepis

3.1亿美元!渤健获得三星Bioepis两款眼科生物仿制药权益

2019-11-07 17:12:26 Xconomy

本文共1048个字,阅读需3分钟

Biogen is bolstering its strategy of selling biosimilars—lower-cost versions of biological drugs that are losing patent protection—with a $100 million deal for rights to two eye products. The drug maker is also expanding its biosimilar scope to include China. Cambridge, MA-based Biogen (NASDAQ: BIIB) struck the deal with Samsung Bioepis, its joint venture with Samsung BioLogics of South Korea. Under the agreement announced Wednesday, Biogen will pay Samsung Bioepis $100 million up front for the rights to SB11, a drug that’s biologically similar to Roche’s drug ranibizumab (Lucentis); and SB15, which references the Regeneron (NASDAQ: REGN) drug aflibercept (Eylea). The Roche and Regeneron drugs, both blockbuster sellers, treat the “wet” form of age-related macular degeneration. Biogen gains the rights to the Samsung Bioepis biosimilars in the US, Canada, Europe, Japan, and Australia. Samsung Bioepis could gain up to $210 million in payments, pegged to milestones. Samsung Bioepis will be responsible for the development of the two biosimilars. The deal also expands Biogen’s commercialization rights for three biosimilars for inflammation. Under a previous agreement with Samsung Bioepis, Biogen has the rights to commercialize those drugs—knockoffs of etanercept, infliximab, and adalimumab—in Europe, and in the case of the etanercept biosimilar, also Japan. Biogen reported $545.1 million in 2018 sales from those biosimilars, a 43 percent increase over the previous year. According to the latest agreement with Samsung Biopeis, Biogen gains exclusive commercialization rights for those drugs in China in exchange for royalties from sales in that market. Biogen also gains an option to extend the term of the agreement covering European commercialization of these drugs. In a prepared statement, Biogen CEO Michel Vounatsos said that the deal with Samsung Bioepis gives his company the potential to grow its biosimilar business globally, while also complementing its presence in eye drugs. Earlier this year, Biogen paid $800 million to acquire Nightstar Therapeutics, a developer of gene therapies for rare eye diseases. Biogen and Samsung BioLogics formed Samsung Bioepis in 2011. At that time, Biogen’s stake in the venture was 15 percent. Last year, Biogen paid $700 million to exercise its right to boost its ownership position to 49.9 percent.
百健(Biogen)公司正在加强其销售生物仿制药的战略。生物仿制药是一种成本较低的生物药物,正在失去专利保护。这家制药公司还在扩大其生物仿制药领域,将中国包括在内。 位于马萨诸塞州坎布里奇的百健(Biogen)公司( NASDAQ : BIIB )与三星 Bioepis 公司达成了协议,后者是其与韩国三星生物逻辑公司的合资企业。根据周三宣布的协议,百健(Biogen)将向三星生物支付1亿美元,以换取 SB11的权利, SB11是一种生物上类似于罗氏(Roche)的药物 ranibizumab ( Lucentis ); SB15是指再生元(Regeneron)( NASDAQ : REN )的药物 aflibicept ( Eyla )。 罗氏( Roche )和瑞金龙(再生元(Regeneron))这两种畅销药物治疗与年龄相关的黄斑变性的“湿性”形式。百健(Biogen)公司在美国、加拿大、欧洲、日本和澳大利亚获得三星生物仿制药的权利。三星生物将获得高达2.1亿美元的付款,与里程碑挂钩。三星生物将负责开发这两种生物仿制药。 该协议还扩大了百健(Biogen)公司对三种用于炎症的生物仿制药类似物的商业化权利。根据之前与三星生物签订的一项协议,百健(Biogen)有权将这些药物——依那西普、英夫利昔单抗和阿达木单抗的仿制品——在欧洲以及在依那西普生物生物仿制药药的情况下,也是日本——商业化。百健(Biogen)报告称,2018年这些生物仿制药的销售额为5.451亿美元,同比增长43%。 根据与三星生物签订的最新协议,百健(Biogen)公司获得这些药物在中国的独家商业化权利,以换取该市场销售的特许权使用费。百健(Biogen)还获得了延长协议期限的选择权,该协议涵盖了这些药物在欧洲的商业化。 百健(Biogen)首席执行官 Michel Vounsos 在一份准备好的声明中表示,与三星 Bioepis 的交易使其公司有潜力在全球范围内发展其生物生物仿制药业务,同时也补充了其在眼科药物领域的存在。今年早些时候,百健(Biogen)斥资8亿美元收购了 Nightstar Therapeutics ,一家研发罕见眼病基因疗法的公司。 百健(Biogen)和 Samsung BioLogics 于2011年组建了三星 Bioepis 。当时,百健(Biogen)在合资企业中的持股比例为15%。去年,百健(Biogen)斥资7亿美元行使了将其所有权提升至49.9%的权利。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文